000			02070nam a22003615i 4500
001			100767
003			ESmaUEC
005			20230102113010.0
006			a||||fo|||| 00| 0
007			cr nn nnnaamaa
008			180927s2018 gw | s |||| 0|eng d
020			_a9783319984285 _9
024	7		_a10.1007/978-3-319-98428-5 _2doi
040			_aES-MaUEC _bspa _cES-MaUEC
050		4	_aRM301.25 2018 EB
100	1		_aNagel, Karen M. _eautor
245	1	0	_aIntroduction to Biologic and Biosimilar Product Development and Analysis _cby Karen M. Nagel.
264		1	_aCham, Switzerland _bSpringer International Publishing _c2018
300			_a1 recurso en línea (XI, 109 páginas 4 ilustraciones a color)
336			_aTexto _btxt _2rdacontent
347			_atext file _bPDF _2
490	0		_aAAPS Introductions in the Pharmaceutical Sciences _x2522-834X
505	0		_aRecombinant DNA Technology -- Therapeutic Proteins -- Therapeutic Antibodies -- Analysis and Regulation of Biologics including Biosimilars.
520	3		_aThe purpose of this book is to give a concise introduction to development and analysis of pharmaceutical biologics for those in the pharmaceutical industry who are switching focus from small molecules to biologics processing, analysis, and delivery. In order to maintain a limited focus, Introduction to Biologic and Biosimilar Product Development and Analysis, will deal only with peptides, proteins and monoclonal antibodies.
650		7	_aIndustria farmacéutica _2embne _9138366
710	2		_aSpringerLink (Online service) _0http://id.loc.gov/authorities/names/no2005046756 _1http://viaf.org/viaf/148105729 _9106996
776	0	8	_iEdición impresa: _z9783319984278
776	0	8	_iEdición impresa: _z9783319984292
856	4	0	_uhttps://go.openathens.net/redirector/universidadeuropea.es?url=https://doi.org/10.1007/978-3-319-98428-5 _zAcceso a este recurso digital (usuarios Universidad Europea de Madrid)
490	0		_aBiomedical and Life Sciences (Springer-11642)
942			_2lcc
998			_aSI _a_alco _a_vill _b07/2019 _cm _dz _ef _feng _ggw _h0
999			_c100767 _d100767 _x1